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Background. Cytochrome P450(CYP)-dependent hydroxy-
lation and epoxygenation metabolites of arachidonic acid (AA)
influence renal vascular tone, salt excretion, and inflamma-
tion. Transgenic rats over expressing both human renin and
angiotensinogen genes (dTGR) feature angiotensin II (Ang II)–
induced organ damage, increased expression of inducible ni-
tric oxide synthase (iNOS), decreased AA hydroxylation, and
epoxygenation. As nitric oxide production via iNOS can inhibit
CYP AA metabolism, we tested the hypothesis that by blocking
iNOS or by supplementing eicosapentanoic acid (EPA), which
can serve as an alternative CYP substrate, Ang II–induced vas-
culopathy could be ameliorated.
Methods. We treated dTGR with the iNOS inhibitor L-N(6)-
(1-iminoethyl) lysine (L-NIL), EPA, and the combination of
both treatments from week 4 to 7.
Results. Immunohistochemistry showed that L-NIL and EPA
reduced glomerular iNOS toward control levels. L-NIL–treated
dTGR showed cardiac hypertrophy and albuminuria similar to
untreated dTGR. EPA and the combination of EPA + L-NIL,
ameliorated organ damage without lowering blood pressure.
EPA and EPA + L-NIL reduced cardiac hypertrophy, albu-
minuria, renal fibronectin expression, and infiltration of mono-
cytes/macrophages, compared to L-NIL and untreated dTGR.
Reactive oxygen species were detected in glomeruli of un-
treated and L-NIL–treated dTGR, but was reduced in the EPA
groups. EPA treatment reduced activator protein-1 (AP-1) ac-
tivation and partially inhibited nuclear factor-kappaB (NF-jB)
activity in kidneys of dTGR.
Conclusion. These results demonstrate that iNOS inhibition
does not protect against Ang II–induced end-organ damage,
while EPA treatment does. Our electromobility shift assay ex-
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periments revealed that EPA protection may involve inhibition
of AP-1– and NF-jB–dependent pathways.
Cytochrome P450 (CYP)-dependent arachidonic acid
(AA) hydroxylation and epoxygenation produces numer-
ous compounds relevant to cardiovascular disease. The
metabolites include 19- and 20-hydroxyeicosatetraenoic
acid (19- and 20-HETE) and four regioisomeric epoxy-
eicosatrienoic acids (5,6-, 8,9-, 11,12- and 14,15-EET).
Members of the CYP4A subfamiliy produce 20-HETE,
whereas the epoxygenation reaction is catalyzed by
CYP2C and CYP2J enzymes [1]. 20-HETE and EETs
play important roles in the regulation of renal vascular
tone, salt excretion, and anti-inflammatory mechanisms
[2]. Both 20-HETE and EETs inhibit salt reabsorption
[3, 4]. A deficiency in tubular expression of 20-HETE–
generating CYP4A enzymes and failure to up-regulate
EET-generating CYP2C enzymes was related to salt-
sensitive hypertension in Dahl rats [5, 6]. 20-HETE is
also an endogenous vasoconstrictor by inhibiting Ca2+-
activated potassium (BK) channels and by activating
Rho-kinase [7, 8]. 20-HETE inhibition reduces blood
pressure in spontaneously hypertensive rats and deoxy-
corticosterone acetate (DOCA) salt-treated rats [9, 10].
In contrast, EETs are potent vasodilators. They activate
BK channels in vascular smooth muscle cells (VSMCs)
and may function as endothelium-derived hyperpolar-
izing factors (EDHF) in different vascular beds [7, 11].
Moreover, 11,12-EET revealed anti-inflammatory prop-
erties by inhibiting tumor necrosis factor-a (TNF-a)-
induced nuclear factor-kappaB (NF-jB) activation in
coronary endothelial cells [12].
Eicosapentaenoic acid (EPA), a major n-3 polyunsatu-
rated fatty acid (PUFA) in fish oil, may serve as an alter-
native substrate for the AA-metabolizing CYP enzymes
[13]. In analogy to AA metabolism, CYP-dependent
EPA conversion results in a set of hydroxylation and
epoxygenation products: 19- and 20-OH-EPA and five
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regioisomeric epoxyeicosatetraenoic acids (EETeTrs).
The biologic activities of these metabolites have only
been partially investigated. Recent studies demonstrated
that EPA epoxides share and even exceed the capacity
of AA epoxides to activate BK channels, to mediate va-
sodolation, and to stimulate cardiac adenosine triphos-
phate (ATP)-sensitive potassium channels [14–16].
We showed earlier that angiotensin II (Ang II) down-
regulates CYP-dependent renal AA metabolism [17, 18].
We speculated that AA epoxygenation products with
anti-inflammatory properties might thereby be reduced,
contributing to uncontrolled inflammation, particularly
in the kidney. We relied on a double transgenic rat
(dTGR) model expressing both the human renin and an-
giotensinogen genes; the animals develop severe vascu-
lopathy and die at age 8 weeks [18, 19]. We reasoned that
by supplementing EPA, we could ameliorate the down-
regulation of CYP-dependent metabolites. Since nitric
oxide overproduction by nitric oxide synthase (iNOS) in
inflamed tissues inhibits CYP metabolism, we hypothe-
sized that iNOS inhibition would increase the effect of
EPA. Therefore, we gave dTGR EPA supplementation,
the iNOS inhibitor L-N(6)-(1-iminoethyl)lysine (L-NIL),
or both.
METHODS
Experiments were conducted in male dTGR and age-
matched Sprague-Dawley rats. The dTGR line and char-
acteristics are described elsewhere [18, 19]. The rats were
purchased from RCC (Fu¨llinsdorf, Switzerland), kept in
rooms at 24 ± 2◦C, were fed with a standard rat diet con-
taining 0.2% sodium by weight, and were allowed free
access to tap water. All American Physiological Society
guidelines were followed and local authorities (permit
# G 408/97) approved the studies. The treatments were
started at week 4 and continued for 3 weeks. Twelve
vehicle-treated (0.9% saline) dTGR, 15 L-NIL–treated
dTGR (3 mg/kg/day intraperitoneally) according to the
dosage used by McCartney-Francis et al [20], 15 EPA-
treated dTGR (7.5 g/kg dry rat food), 15 EPA + L-NIL–
treated dTGR, and six nontransgenic Sprague-Dawley
rats were used in the study. Due to the small size of the
rat tail, the first blood pressure measurements were per-
formed at week 5 by tail-cuff under light ether anesthe-
sia 20 hours after the last L-NIL dose. Urine samples
were collected over a 24-hour period. Urinary rat albu-
min was measured by enzyme-linked immunosorbent as-
say (ELISA) (Celltrend, Lu¨ckenwalde, Germany). Rats
were killed at age 7 weeks. The kidneys and hearts were
washed with ice-cold saline, blotted dry, and weighed. For
electrophoretic mobility shift assay (EMSA) of NF-jB
and activator protein-1 (AP-1), the tissues were snap-
frozen in liquid nitrogen, for immunohistochemistry in
isopentane (−35◦C), and stored at −80◦C.
Renal microsomal AA and EPA metabolism
Microsomes were prepared from freshly dissected kid-
neys. AA as well as EPA hydroxylase and epoxygenase
activities were determined as described previously [17].
Briefly renal microsomes (80 lg of protein in a total vol-
ume of 0.1 mL) were incubated in 50 mmol/L Tris/HCL
buffer, pH 7.5, with 10 nmol [1-14C] AA (0.55 × 106 dpm)
and 10 nmol [1-14C] EPA (0.55 × 106 dpm), respectively,
in the presence of nicotinamide adenine dinucleotide
phosphate (NADPH) (0.5 mmol/L) for 20 minutes at
37◦C. The reaction products were extracted into ethyl
acetate and resolved by reverse-phase high-pressure liq-
uid chromatography (RP-HPLC) as described [17]. AA
and EPA hydroxylase activities were determined as the
sum of 19- and 20-HETE as well as 19- and 20-OH-EPA,
respectively. AA and EPA epoxygenase activities were
determined as the sum of EETs and corresponding di-
hydroxyeicosatrienoic acids (DHETs) as well as the sum
of the synthesized EETeTrs and corresponding dihydrox-
yeicosatetraenoic acids (DHETeTr), respectively. All ac-
tivities are given in nanomoles of the respective metabo-
lites produced per minute and milligrams of microsomal
protein.
Immunohistochemistry
Frozen kidneys were cryosectioned at 6 lm thick-
ness and stained by immunofluorescence or the al-
kaline phosphatase-antialkaline phosphatase (APAAP)
technique as described earlier [18, 21]. The sections
were fixed with cold acetone, washed with Tris-buffered
saline (TBS), and blocked with 10% normal donkey
serum (Dianova, Hamburg, Germany) for 30 minutes
and incubated with primary monoclonal antibody against
monocyte/macrophages (ED-1) (Serotec, Wiesbaden,
Germany) for 60 minutes in a humid chamber at room
temperature. After washing with TBS, the sections were
incubated with a bridging antibody (rabbit-antimouse
IgG) (Dako, Hamburg, Germany) for 30 minutes at room
temperature and washed again with TBS. The APAAP
complex (Dako) was applied and the sections were
incubated for 30 minutes at room temperature.
The immunoreactivity was visualized by develop-
ment in a mixture of naphthol-AS-BI-phosphate
(Sigma, Schnelldorf, Germany) with neufuchsin (Merck,
Darmstadt, Germany). Endogenous alkaline phos-
phatase was blocked by addition of 10 mmol/L levamisole
(Sigma, Germany) to the substrate solution. The sec-
tions were slightly counterstained in Mayer’s hemalaun
(Merck), blued in a tap water, and mounted with GelTol
(Coulterimmunotech, Marseille, France). Semiquantita-
tive scoring of infiltrated ED-1–positive cells in the kid-
ney was performed using computerized cell count pro-
gram (KS 300 3.0) (Zeiss, Go¨ttingen, Germany). Fifteen
different cortical areas of each kidney (N = 5 in all
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groups) were analyzed. For quantification of perivascular
macrophage infiltration, all selected view fields included a
small vessel in their analysis. The samples were examined
without knowledge of the rats’ identity.
For immunofluorescence staining, after incubation
with primary polyclonal antibodies against rat fibronectin
(Paesel, Frankfurt, Germany) and iNOS (iNOS/NOS2)
(ABR, Golden, CO, USA) and washing with TBS, the
sections were incubated with Cy3-conjugated secondary
antibodies (donkey antirabbit IgG-Cy3) (Dianova) for
60 minutes. After a final washing with TBS, slides were
mounted in Vectashield mounting medium (Vector Lab-
oratories, Burlingame, CA, USA). Preparations were an-
alyzed under a Zeiss Axioplan-2 microscope (Zeiss) and
digital photographed using AxioVision 2 multi channel
image processing system (Zeiss).
Oxidative fluorescent microtopography
The redox-sensitive fluorophore hydroethidine
(Molecular Probes, Eugene, OR, USA) was used to
evaluate the production of O2− in situ as described
previously [22]. Freshly cut kidney cryosections (6 lm)
were placed on glass slides, topically incubated with
hydroethidine (HE) (5 lmol/L) for 30 minutes. After
a 30-minute incubation period, during which HE was
oxidized to the fluorophore ethidium, images were
obtained using a Zeiss Axioplan-2 microscope (Zeiss)
and digital photographed using AxioVision 2 multi-
channel image processing system (Zeiss).
EMSA
Preparation of kidney extracts and EMSA for the tran-
scription factor NF-jB were performed as described ear-
lier [23, 24]. Nuclear extracts (5 lg) were incubated in
binding reaction medium [2 lg poly dI-dC, 1 lg bovine
serum albumin (BSA), 1 mmol/L dithiothreitol (DTT),
20 mmol/L Hepes, pH 8.4, 60 mmol/L KCl, and 8%
Ficoll] with 0.5 ng of 32P-deoxyadenosine triphosphate
(dATP) end-labeled oligonucleotide, containing the NF-
jB binding site from the major histocompatibility com-
plex (MHC) enhancer (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) (H2K) (5′-gatcCAG GGC TGG GGA
TTC CCC-ATC TCC ACA GG) at 30◦C for 30 min-
utes. In competition assays 50 or 100 ng unlabeled H2K
oligonucleotides were used. For supershift assay, 1 lg of
anti-p50, anti-p65 (Santa Cruz Biotechnology) was added
20 minutes to the homogenates before addition of the la-
beled probe. For AP-1 oligonucleotides containing the
consensus sequence for AP-1 (Santa Cruz Biotechnol-
ogy) (5′-GAT CGA ACT GAC CGC CCG CCG CCC
GT-3′) were radiolabeled with c -32P-dATP with the use
of T4 polynucleotide kinase by standard methods. For
AP-1 supershift assay, 1 lg of anti-c-fos, anti-c-jun, anti-
Fra-1, anti-Fra-2, anti-JunB, and anti-JunD (Santa Cruz
Biotechnology) was used. In competition assays 50 ng
unlabeled H2K or AP-1 oligonucleotides were used.
Western blot analysis
Renal microsomal protein (15 lg per lane) was sep-
arated on 10% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) and immunoblotting
was performed as we have described previously [17].
Protein concentrations were quantified by the Lowry
method. Primary antibodies used were goat antisera
against rat CYP4A1 (reacts with all rat CYP4A iso-
forms) and rat CYP2C11 (both Daiichi Pure Chemicals
Co., Tokyo, Japan). Peroxidase-conjugated secondary an-
tibodies were from Sigma. Blots were developed with
a chemiluminescens substrate from Roche and evalu-
ated with the Image Reader LAS-1000 (Fujifilm, Kleve,
Germany).
Statistical analysis
Data are presented as mean ± SEM. Statistically signif-
icant differences in mean values were tested by analysis
of variance (ANOVA), blood pressure by repeated mea-
sures ANOVA, and the Scheffe´ test as indicated. A value
of P < 0.05 was considered statistically significant. The
data were analyzed using Statview statistical software.
RESULTS
Seven of 15 vehicle-treated dTGR died before sacri-
fice. L-NIL treatment did not improve survival, as six of
15 L-NIL–treated dTGR died. EPA treatment reduced
mortality to one of 15. In the combined EPA + L-
NIL treatment group mortality was reduced to zero. No
Sprague-Dawley rats died. The EPA effects on mortality
were significant.
L-NIL–treated dTGR showed a paradoxic effect on
systolic blood pressure. While blood pressures in L-NIL
and L-NIL + EPA dTGR were significantly lower at week
5 compared to untreated and EPA-treated dTGR (135 ±
3 vs. 146 ± 4 vs. 167 ± 4 vs. 165 ± 6 mm Hg, respectively),
blood pressure increased by 40 mm Hg within 1 week
to vehicle-treated dTGR levels (Fig. 1A). However, all
dTGR groups had similarly elevated blood pressures at
week 7 (Fig. 1A). Cardiac hypertrophy was reduced only
in the EPA-treated groups (Fig. 1B). Albuminuria was se-
vere in vehicle-treated dTGR, but was markedly reduced
in the EPA-treated groups. L-NIL alone did not reduce,
but slightly increased albumin excretion (Fig. 1C).
L-NIL and EPA treatment reduced glomerular iNOS
expression as shown by immunofluorescent staining
(Fig. 2). Both the EPA and the L-NIL–treated groups
showed reduced staining compared to vehicle treatment.
Nevertheless, L-NIL treatment did not ameliorate organ
damage. In the kidney, fibrosis, measured as fibronectin
expression, was reduced only by EPA treatments (Fig. 3).
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Fig. 1. Tail-cuff blood pressure measurements were obtained at weeks 5, 6 and 7. (A)Treatments were begun at week 4. At week 5, the L-N(6)-
(1-iminoethyl) lysine (L-NIL) and the L-NIL + eicosapentanoic acid (EPA)–treated groups had lower blood pressures. At week 7, blood pressure
measurements of all groups were similar. (B) Cardiac hypertrophy was partially decreased by EPA alone and EPA in combination with L-NIL. (C)
Albuminuria was markedly reduced by the EPA treatment without or with L-NIL, but slightly increased with L-NIL treatment alone.
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dTGR
dTGR+L−NIL dTGR+EPA+L−NIL
dTGR+EPA SD
iNOS
Fig. 2. Glomerular inducible nitric oxide synthase (iNOS) staining in vehicle-treated double transgenic rat (dTGR), L-N(6)-(1-iminoethyl) lysine
(L-NIL)-treated dTGR, eicosapentanoic acid (EPA)-treated dTGR, EPA + L-NIL–treated dTGR, and Srague-Dawley (SD) rats. L-NIL, L-NIL
+ EPA, and EPA alone all reduced iNOS staining.
dTGR+EPA+L−NILdTGR+L−NIL
dTGR dTGR+EPA SD
Fibronectin
Fig. 3. Renal interstitial fibrosis is shown as fibronectin staining in vehicle-treated double transgenic rat (dTGR), L-N(6)-(1-iminoethyl) lysine
(L-NIL)–treated dTGR, eicosapentanoic acid (EPA)-treated dTGR, EPA + L-NIL–treated dTGR, and Srague-Dawley (SD) rats.
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dTGR+L−NIL dTGR+L−NIL+EPA
dTGR dTGR+EPA SD
Fig. 4. Reactive oxygen species generation
of glomeruli is shown as ethidium stain-
ing in vehicle-treated double transgenic rat
(dTGR), L-N(6)-(l-iminoethyl) lysine (L-
NIL)–treated dTGR, eicosapentanoic acid
(EPA)-treated dTGR, EPA + L-NIL–
treated dTGR, and Sprague-Dawley (SD)
rats.
The same was true for reactive oxygen species generation
in glomeruli as shown by the fluorophore hydroethidine
(Fig. 4). AP-1 activation was significantly reduced to-
ward Sprague-Dawley control level in both EPA groups
compared with vehicle-treated or L-NIL–treated dTGR
(Fig. 5A). The transcription factor NF-jB was strongly
activated in dTGR kidneys. This activation was partially
inhibited by EPA treatment (Fig. 5B). Renal inflamma-
tion, measured as monocytes/macrophages infiltration,
was decreased to Sprague-Dawley control level by EPA
treatment (Fig. 5C).
As shown in Figure 6A (left panel), renal microsomes
isolated from Sprague-Dawley rats converted AA to
19-/20-HETE and to a series of EETs and correspond-
ing DHETs. None of these metabolites was produced
when NADPH was omitted from the reaction mixtures.
20-HETE represented the major product of CYP4A-
dependent AA hydroxylation. This metabolite migrated
with a retention time of 15.8 minutes in the RP-HPLC
system used. CYP2C-dependent AA epoxygenation pro-
duced 14,15-, 11,12-, and 8,9-EETs (peaks at 23.5, 24.9,
and 25.3 minutes, respectively). The corresponding di-
ols resulted from subsequent hydrolysis of the EETs
catalyzed by soluble epoxide hydrolase and comprised
14,15-, 11,12-, and 8,9-DHET migrating at 12.5, 13.7, and
14.5 minutes, respectively.
The renal microsomal CYP enzymes catalyzed not
only the hydroxylation and epoxygenation of AA, but
also accepted EPA as an efficient alternative substrate
(Fig. 6A, right panel). EPA was hydroxylated to 19-/20-
OH EPA (peak at 14.2 minutes) with a rate of 453 ±
26 pmol/min/mg that clearly exceeded the corresponding
AA hydroxylase activity (208 ± 12 pmol/min/mg). The
EPA epoxygenase activity reached 115±12 pmol/min/mg
and was almost identical to the AA epoxygenase activity
(108 ± 10 pmol/min/mg). However, the regional selec-
tivities of AA and EPA epoxygenation were completely
different. AA was converted to a mixture of regioiso-
meric EETs/DHETs and among them 11,12-EET and
11,12-DHET were the dominant products. In contrast,
EPA was almost exclusively converted to 17,18-EETeTr
(Fig. 6A, right panel) (peak at 19.6 minutes) demon-
strating that the 17,18-double bond which distinguishes
EPA from AA is a preferred site of CYP-dependent
epoxygenation.
Renal microsomes isolated from dTGR and the dif-
ferent treatment groups produced essentially the same
AA and EPA metabolite patterns as described earlier
for the Sprague-Dawley controls. However, the rates of
metabolite production were significantly lower in dTGR
compared to the Sprague-Dawley controls, indicating a
down-regulation of the CYP enzymes converting AA and
EPA. AA and EPA hydroxylase activities were reduced
to about 45% and the epoxygenase activities to 28%
and 35% of the control values (Fig. 6B to E). Neither
the hydroxylase nor the epoxygenase activities were in-
duced by EPA, the combination EPA + L-NIL, or L-
NIL treatment alone (Fig. 6B to E). Western blotting
revealed a significant increase in CYP4A protein lev-
els in both the EPA and the L-NIL treatment groups
compared to vehicle-treated dTGR. The CYP4A protein
level in the EPA group even exceeded that of Sprague-
Dawley rats (Fig. 6F). Nevertheless, this protein increase
was not correlated with an increased hydroxylase activity.
In vehicle-treated dTGR, microsomal CYP2C11 protein
levels reached only about 25% of the Sprague-Dawley
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Fig. 5. Activating protein-1 (AP-1) and nu-
clear factor-kappaB (NF-jB) DNA binding
activity in nuclear renal extracts by elec-
trophoretic mobility shift assay (EMSA). (A)
AP-1 activation was significantly reduced by
the eicosapentanoic acid (EPA) treatments.
(B) NF-jB activation was partially inhib-
ited by EPA treatment. (C) EPA suppresses
monocyte/macrophage (ED-1) infiltration in
the kidney. Vehicle-treated and L-N(6)-(1-
iminoethyl) lysine (L-NIL)–treated double
transgenic rat (dTGR) kidneys showed in-
creased infiltration of ED-1+ cells.
controls. This low level was increased to about 60% by L-
NIL, but was not altered by either EPA or EPA + L-NIL
treatment (Fig. 6G).
DISCUSSION
Our study demonstrates that EPA supplementation,
but not inhibition of iNOS protects dTGR from renal
damage. EPA exerted strong anti-inflammatory and an-
tifibrotic effects and ameliorated albuminuria. L-NIL
clearly inhibited the glomerular expression of iNOS, but
rather worsened than ameliorated renal damage. L-NIL
treatment of dTGR resulted in a strong down-regulation
of glomerular iNOS expression as shown by immuno-
histochemistry. These findings show that L-NIL not only
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Fig. 6. Representative high-pressure liquid
chromatography (HPLC) chromatograms
show the metabolite pattern produced dur-
ing conversion of arachidonic acid (AA) and
eicosapentanoic acid (EPA) by renal micro-
somes isolated from Sprague-Dawley (SD)
control rats. (A) AA was converted to 19-/20-
HETE and to a series of epoxyeicosatrienoic
acids (EETs) and corresponding diols [di-
hydroxyeicosatrienoic acids (DHETs)]. EPA
was hydroxylated to 19-/20-OH EPA and
epoxidized predominantly to 17,18-EETeTr.
AA and EPA hydroxylase (B and D) and
AA and EPA epoxygenase (C and E) ac-
tivities in renal microsomes were strongly
reduced in double transgenic rat (dTGR)
compared to Sprague-Dawley rats and were
not influenced by the treatments. Western
blotting for the cytochrome P450 enyzme
(CYP4A) (F) revealed a significant increase
in protein levels in the EPA treatment group
compared to vehicle-treated dTGR. Micro-
somal CYP2C11 (G) was only increased by
L-N(6)-(1-iminoethyl) lysine (L-NIL) alone
compared to vehicle-treated dTGR but nei-
ther in the the EPA nor EPA + L-NIL–treated
groups.
functioned as an inhibitor of iNOS activity, but also si-
multaneously affected the regulation of iNOS expres-
sion. As a possible explanation, there are several reports
indicating autoregulation of iNOS by nitric oxide itself
[25]. In gromerular mesangial cells, nitric oxide seems to
function in a positive feedback loop that enhances iNOS
expression at the mRNA and protein level [26]. Conse-
quently, inhibition of nitric oxide production by L-NIL
can be expected to interrupt this positive feedback loop
and to result in the observed reduction of iNOS protein
levels.
In the dTGR model, high local Ang II concentra-
tions trigger a cascade of events that involves oxidative
stress, activation of proinflammatory transcription fac-
tors, expression of adhesion molecules, cytokines and
chemokines, monocyte/macrophage infiltration, and fi-
brosis [18, 19, 21, 24]. Glomerular iNOS induction is
one component of this cascade. In the present study,
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Fig. 6. continued.
L-NIL effectively blocked iNOS expression as judged by
immunohistochemistry. However, no end-organ protec-
tion ensued. Glomerular reactive oxygen species gener-
ation continued unabated, and we observed increased
fibronectin expression and macrophage infiltration.
Moreover, AP-1 and NF-jB activation were not de-
creased by L-NIL. In earlier studies, iNOS inhibition
had variable effects indicating that enhanced nitric ox-
ide production may have beneficial or detrimental effects
depending on the pathophysiolgic condition [26–28]. In
agreement with our study, iNOS blockade by L-NIL ag-
gravated proteinuria in several rat models of glomeru-
lonephritis [29–31]. These results suggest a protective
role of enhanced nitric oxide production in established
renal inflammation. Possibly, iNOS-derived nitric oxide
may function as a feedback inhibitor of inflammatory pro-
cesses by inhibiting NF-jB and AP-1 signaling [32, 33].
However, the actual mechanisms are probably more com-
plex since nitric oxide was shown to interact with various
signal transduction pathways, to counteract reactive oxy-
gen species generation and to modulate the expression of
many different genes potentially involved in glomerular
remodeling [26, 34].
L-NIL treatment did not restore the low CYP-
dependent AA hydroxylase and epoxygenase activities
characteristic for dTGR. Down-regulation of CYP en-
zymes during inflammation is a general phenomenon
and enhanced nitric oxide production may interfere at
different levels with CYP expression and activities [35].
All CYP enzymes, including the rat renal 20-HETE and
EET producing isoforms [36], can bind nitric oxide to
the prosthetic heme group resulting in an inhibition of
their enzymatic activities. This type of reversible CYP-
nitric oxide interaction is not excluded by our findings
since we determined the capacities to produce 20-HETE
and EETs using isolated renal microsomes. Moreover,
isoform-selective effects, including irreversible inactiva-
tion by peroxynitrite [37] and inhibition of expression
by direct interaction of nitric oxide with transcription
factors, have been reported [38]. Such irreversible nitric
oxide effects may have contributed to the strong down-
regulation of CYP2C11 protein levels in dTGR, since we
observed a partial recovery after L-NIL treatment. How-
ever, our results exclude a major role of iNOS-derived
nitric oxide in the irreversible down-regulation of those
CYP enzymes responsible for 20-HETE (CYP4As) and
EET production (predominantly CYP2C23) [17, 18]. Ni-
tric oxide–independent down-regulation during inflam-
mation was shown also for several other CYP isoforms
but the actual mechanisms remain to be defined [35].
In contrast to L-NIL treatment, EPA supplementation
clearly ameliorated Ang II–induced renal damage in our
model. Numerous animal and clinical studies over the last
25 years revealed that dietary n-3 PUFAs such as EPA
and docosahexaenoic acid (DHA) have beneficial effects
in cardiovascular diseases [39–41]. Antiatherosclerotic,
anti-inflammatory, antithrombotic, vasorelaxant, antihy-
pertensive, and cardioprotective properties might ac-
count for the beneficial actions of EPA and DHA. The
capacity of n-3 PUFAs to ameliorate renal damage is
not restricted to our transgenic rat model. EPA was re-
ported to retard the progression of diabetic nephropa-
thy in streptozotocin-treated rats [42] and to prevent
the development of glomerulosclerosis in a 5/6 renal
ablation model [43]. Moreover, n-3 PUFAs delayed
proteinuria, lowered blood pressure and improved the
antioxidant status in spontaneously hypertensive rats
[44, 45]. In our model, EPA alone or in combina-
tion with L-NIL significantly reduced albuminuria and
fibronectin expression, while blood pressure was not
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affected. However, EPA efficiently reduced reactive oxy-
gen species generation, activation of AP-1 and NF-jB,
and the infiltration of macrophages suggesting a strong
anti-inflammatory effect. Moreover, glomerular expres-
sion of iNOS was down-regulated. The EPA effect on
AP-1 and NF-jB could explain this finding since the pro-
moter region of iNOS contains binding sites for both
transcription factors [25]. Taken together, these results
indicate that EPA efficiently interrupted the entire in-
flammatory cascade triggered by Ang II in dTGR.
The mechanisms of how n-3 PUFAs can inhibit proin-
flammatory transcription factor activation are not fully
understood. In vitro studies suggested that EPA inhib-
ited IjB-degradation and therefore repressed NF-jB
activation [46]. On the other hand, oxidized EPA was re-
ported to activate the peroxisome proliferator activated
receptor alpha (PPAR-a), a known inhibitor of NF-jB
signaling [47]. We found previously that PPAR-a acti-
vation is highly protective in our dTGR model [18]. To
our knowledge, this study is the first showing inhibition
of AP-1 activation by EPA in renal inflammation. In a
mouse epidermal cell model, DHA and EPA inhibited
AP-1 activation by a mitogen-activated protein (MAP)
kinase-independent mechanism that has not yet been de-
fined [48].
Whether the beneficial effects attributed to EPA-rich
diets are exerted by EPA itself, by one of its potential
metabolites, or result from reduced AA metabolite gen-
eration is unclear. EPA is known to compete with AA
for the conversion by cyclooxygenases and lipoxygenases
leading to a reduced production of AA-derived proin-
flammatory eicosanoids and to the generation of alter-
native less potent EPA-derived metabolites [49]. More-
over, EPA seems to be the preferred substrate for several
AA-metabolizing CYP enzymes [14, 50]. Thus, a switch
to CYP-dependent EPA metabolite formation may have
contributed to the protective effects of EPA in our dTGR
model, although EPA supplementation did not induce
the CYP activities. As shown here, rat renal microsomes
produce 19-,20-OH-EPA and 17,18-EETeTr as the main
products of EPA hydroxylation and EPA epoxygenation.
The biologic activity of 17,18-EETeTr resembles that of
11,12-EET. 17,18-EETeTr acts as a powerful activator
of BK channels [14]. Whether or not 17,18-EETeTr also
shares the anti-inflammatory properties known for 11,12-
EET is not known for certain [12].
In addition to the anti-inflammatory effects, n-3 PU-
FAs were reported to suppress mesangial cell prolifera-
tion [51]. EPA inhibited epidermal and platelet-derived
growth factor (PDGF)-stimulated rat mesangial cell mi-
togenesis [52, 53]. Such effects may play a pivotal role
in preventing glomerular remodeling and may also have
contributed to the amelioraration of renal damage in our
dTGR model. Furthermore, EPA could be vasoprotec-
tive by inhibiting sphingosyl phosphorylcholine (SPC), a
messenger for Rho-kinase–mediated Ca2+-sensitization
of vascular smooth muscle (VSM) contraction [54]. Fur-
ther studies are required to elucidate the underlying
mechanisms involved in the clinically significant antipro-
liferative and anti-inflammatory effects of n-3 PUFAs.
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